Speaker Profile
M.D., Executive Chairman & Co-Founder, Allogene Tx
Biography
Arie S. Belldegrun is a trailblazing urologiconcologistturnedbiotechentrepreneur whose companybuilding spreefrom Agensys and Cougar to Kite Pharmahelped usher in the first FD Aapproved CART therapy and led to Kites $11.9 billion sale to Gilead Sciences. After that landmark exit, he cofounded Allogene Therapeutics and stillserves as its Executive Chairman, steering the next wave of offtheshelf (allogeneic) CART cell products toward the clinic. Beyond Allogene, Belldegrun deploys capital through Bellco Capital, Two River, Symbiotic Capital, Vida Ventures, and the realestate venture Breakthrough Properties, nurturing a constellation of startups thattranslate science into patient impact. Over three decades on UCL As faculty, he has authored 500plus scientificpapers, mentored a generation of physicianscientists, and kept patientbenefit at the center of every dealcementing his reputation as one of precision medicines most influential builders.
Talk
AI and Data Sciences Showcase:
OncoNex
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Priti Hegde, Kite Pharma
PMWC Award Ceremony
• Michel Sadelain, Columbia University
• Arie S. Belldegrun, Allogene Therapeutics
Keynote: Engineering the Future: Innovations in CAR-T Therapy Design
• Michel Sadelain, Columbia University
Keynote: The Industrialization of Cell Therapy:From Autologous Pioneers to Allogeneic Frontiers
• Arie S. Belldegrun, Allogene Therapeutics
Next Generation CAR-T Cell Therapies: Expanding Targets and Enhancing Designs
• Chair: David Barrett, Kite Pharma
• Carl June, University of Pennsylvania
• Michel Sadelain, Columbia University
Tumor-Infiltrating Lymphocytes (TILs): Advances and Challenges in Solid Tumors
• Chair: Allison Betof Warner, Stanford University
• George Coukos, Ludwig Institute for Cancer Research
• Max Julve, Stanford
• Stephanie Goff, NIH/NCI
Allogeneic & In Vivo Cell Therapies: Manufacturing & Clinical Progress
• Chair: Arie S. Belldegrun, Allogene Therapeutics
• Zach Roberts, Allogene Therapeutics
• Adrian Bot, Capstan Therapeutics
• Aliya Omer, AstraZeneca
• Priti Hegde, Kite Pharma
Smart Scaling: Leverating AI & Automation to De-Risk Advanced Therapy Manufacturing
• Chair: Stacie Calad-Thomson
• Samuel Rodriques, FutureHouse
• Manuel Leonetti, Biohub
• Fabian Gerlinghaus, Cellares
Designing Automated Platforms for Scalable Cell Therapy Manufacturing
• Fabian Gerlinghaus, Cellares
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
• Daniel Getts, Myloid Therapeutics
Operationalizing Cell & Gene Therapy Trials in a Large Health System
•Snehit Prabhu, Stanford
Gene Editing & Synthetic Biology for Therapy
• Chair: Trevor Martin, Mammoth Biosciences
• Ken Drazan, ArsenalBio
• Lynn Seely, Lyell
• Kole T. Roybal, Parker Institute
• David Kirn, 4DMT
